PUBLISHER: DelveInsight | PRODUCT CODE: 1377970
PUBLISHER: DelveInsight | PRODUCT CODE: 1377970
“"VXA-A1.1 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about VXA-A1.1 for seasonal influenza in the seven major markets. A detailed picture of the VXA-A1.1 for seasonal influenza in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the VXA-A1.1 for seasonal influenza. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the VXA-A1.1 market forecast analysis for seasonal influenza in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in seasonal influenza.
VXA-A1.1, an investigational oral tablet flu vaccine under development by Vaxart, had cellular correlates of protection against influenza infection. VXA-A1.1 utilizes TLR adjuvant by encoding dsRNA and an H1N1 HA transgene in a recombinant adenovirus type 5 (Ad5) vector. TLR adjuvant is double-stranded RNA (dsRNA), which binds TLR3 and activates inflammatory pathways. This oral vaccine has been studied in four clinical trials with 285 participants between 18 years and 49 years. One trial reported increased antibody responses to matched H1N1 strains with an average of 7.7-fold increases in HAI titers and 29-fold increases in microneutralization titers after vaccination.
It is a prophylactic vaccine candidate that targets a range of infectious diseases, including SARS-CoV-2 (the virus that causes coronavirus disease 2019 ("COVID-19")), norovirus (a widespread cause of acute gastro-intestinal enteritis), seasonal influenza and respiratory syncytial virus ("RSV").
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
VXA-A1.1 Analytical Perspective by DelveInsight
This report provides a detailed market assessment of VXA-A1.1 for seasonal influenza in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.
The report provides the clinical trials information of VXA-A1.1 for seasonal influenza covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions